Risk of major arterial thromboembolic events similar between ranibizumab, aflibercept
Although no significant difference in the risk of major arterial thromboembolic events (ATEs) and glaucoma was noted between patients treated with intravitreal aflibercept injection and with intravitreal ranibizumab injection in a recent study, a subgroup analysis suggests aflibercept might be safe for use in older patients.
In this retrospective, nationwide cohort study, patients aged >50 years with ≥1 pharmacy claim for intravitreal ranibizumab injection and aflibercept injection between 2011 and 2016 were included. A total of 15, 611 patients were treated with intravitreal ranibizumab and 3867 patients were treated with intravitreal aflibercept.
During the 2-year follow-up period, there was no significant difference between intravitreal ranibizumab and aflibercept injection for arterial thromboembolic risk.
Compared to patients treated with ranibizumab, those receiving aflibercept had a significantly lower risk of arterial thromboembolic if they were aged >65 years and without coronary artery disease.
There was no difference in the risk of developing glaucoma after intravitreal injection between the treatment groups.
Chang YH, Chien LN, Chen WT, et al. Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study. PLoS One. 2022;17(4):e0267088. doi: 10.1371/journal.pone.0267088. PMID: 35436315.